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259 Can Burkholderia Cepacia complex (BCC) be eradicated with
nebulised Amiloride and Tobi?
R. Ball1, K.G. Brownlee1, A. Duff1, T.W. Lee1, S.P. Conway1. 1St James’
Hospital, Leeds, United Kingdom
Introduction: BCC is a highly transmissible gram-negative organism with inherent
resistance to multiple antibiotics, associated with greater virulence. Consequences
of chronic infection include; accelerated decline in lung function and nutritional
status, added burden of treatment, psychosocial issues linked to segregation and
a reduction in quality of life. A group case study in adults [1] showed potential
synergistic effects of nebulised Amiloride and Tobramycin for BCC eradication.
Aim: To investigate if this regimen could eradicate BCC infection in children with
CF.
Method: Seven patients (5 female; mean age 15.2 yrs [range12−16]; median dura-
tion of infection 14mths [1–128]; 3 genomovar[gen]IIIA ET-12, 3 genII, 1 genIV),
who cultured BCC, were prescribed preservative-free nebulised Amiloride (1.5mg)
followed by Tobi® (300mg), twice daily via eﬂowrapid® for 6 months. Adherence
was assessed by parent log, prescription rate and used-bottle count.
Results: BCC was eradicated in only 1 patient (gen IV, culture +ve for 4 weeks
prior to therapy, adherence 96.4%). During the course of the study there was no
signiﬁcant change in FEV1 (p = 0.11), mean change = −0.0086 L per wk, equivalent
to mean annual decline of 28%. Two patients, both genII accounted for the majority
of this decline. Median adherence by used-bottle count was 62.8% (mean = 63.3%,
range 6.9−96.4). 4 patients discontinued the study early between 3 and 4.5 mths
due to haemoptysis or clinical deterioration.
Conclusion: Mean lung function remained stable although 4 subjects stopped the
therapy early. In 6 children with chronic BCC genIIIA or II infection nebulised
Amiloride and Tobi® did not eradicate these organisms. However, the child with a
recent growth of genIV remains infection-free 14 months later.
Reference(s)
[1] Middleton PG et al ERJ 2005;26:305–308.
260 Efﬁcacy of Bramitob® on eradication of Ps. aeruginosa (PA)
D.T. Drinkovic´1, D. Tjesˇic´-D1, J. Kelecˇic´1, A. Votava-Raic´1, A. Gagro1,
J. Vranesˇ1. 1Dept. of Pediatrics, University Hospital Centre & School of Medicine,
Zagreb, Croatia
Since 2007. tobramycin inhalations are available in Croatia. Here we report on
ﬁrst experiences with Bramitob® at our CF unit, University Hospital Center in
Zagreb regarding PA colonization. In a 18-month period (Apr.07-Sept.08) 27 of
our patients (48.2%) had PA isolation from sputa. They were treated with inhaled
tobramycin 300mg twice daily in 28 days on/off cycles until 2 consecutive PA
negative cultures were obtained and were afterwords followed at least 6 months.
Regarding microbiological results we divided patients in 3 outcome groups at the
end of observation: A 10 patients (37%) remained chronically infected with PA;
B 6 patients (22.2%) were recolonized within 6 months after a negative culture;
C 11 patients (40.8%) had negative cultures for 6 months.
These groups differed at the beginning of treatment: A subjects with persistent PA
colonization aged 8−25 yrs had initially ↑ count of polymorphonuclear lymphocytes
(PMN) >25 in sputa and FEV1 ranged 25.3−80.8%pred. In group B aged 12−21 yrs,
the PMN count was 1025 and FEV1 ranged 49.0−78.4%pred. In the best outcome
group C subjects aged 2−18 yrs had PMN 0−25 and FEV1 ranged 6080%pred.
They had previously 3 positive PA cultures. Treatment was connected with a
general decrease in PMN count and a mostly favorable effect on lung function
in all groups, but with large variability in responses (N.S.). The primary outcome
goal (PA eradication) was archived in younger subjects with low PMN count and a
shorter PA colonization (C). For this up to 3 Bramitob® cycles were needed. Data
from this small sample speak in favor of early treatment for PA and the importance
of regular sputum controls. Patients with persistent/recurrent PA colonization (A, B)
beneﬁted mainly from decrease in PMN count.
261 TOBI 300 in Bulgarian cystic ﬁbrosis patients
I.O. Galeva1, M.I. Iankova1, R. Markova1. 1Pediatric Clinic, University Hospital
“Alexandrovska”, Soﬁa, Bulgaria
Aim: To assess the drug tolerance and the inﬂuences on the Ps. Aeruginosa (PA)
in sputum, lung functional parameters, body mass index (BMI) and the changes in
the quality of life while using TOBI 300 in Bulgarian cystic ﬁbrosis (CF) patients.
Methods: A number of 42 CF patients among which 17 children (aged 6 y-18 y,
8 boys and 9 girls) and 25 adults (12M and 13F, aged 19 y-28 y) have received
TOBI 300 through inhalation, twice daily for 4 weeks, followed by interrupting the
treatment during the next 4 weeks. All CF patients were pancreatic insufﬁcient
and have received their common CF treatment. PA in their sputum had been
established more than 3 times for the last two years and at the beginning of the
TOBI treatment all patients did not show lung exacerbation evidences. Clinical
status, lung functional tests (LFT), PA in sputum, BMI and quality assessment of
CF life have been followed.
Results: With the exception of one 15 y boy, the clinical status of all CF has not
shown need for hospitalization during the observation period (>4 months). PA in
sputum has disappeared in 10 adult CF (40.0%) and in 11 CF children (64.7%).
LFT’s have shown improvement in about two thirds of the CF children (n = 7) and
in 28% of the adults (n = 7). Appetite in most patients has improved, nevertheless
signiﬁcant changes in BMI have not been found. Better quality of CF life (answering
positive on 7 or more questions from the questionnaire) has been found in more
than 80% of the CF patients. Drug adverse effects have not been noticed in any of
CF patients.
Conclusions: Treatment with TOBI 300 through inhalations twice daily has shown
adequate therapeutic results in our CF patients and has been well tolerated.
262 Long term impact of azithromycin in paediatric cystic ﬁbrosis
patients
J. Fermeiro1, S. Castanhinha1, L. Pereira1, C. Barreto1. 1Cystic Fibrosis Centre,
Paediatric Department, University Hospital of Santa Maria, Lisbon, Portugal
Background: As inﬂammation plays a crucial role in cystic ﬁbrosis (CF) pathogen-
esis, macrolides may be a valuable therapeutic strategy due to their well documented
anti-inﬂammatory effects.
Aims: To evaluate the clinical and microbiological impact of azithromycin treatment
in paediatric CF patients (pts) during the ﬁrst year after its initiation, namely changes
in FEV1% predicted, body mass index (BMI) percentile, number of hospitalization
and antibiotic treatment days, percentage of mucoid P. aeruginosa isolates and
proﬁle of adverse effects.
Methods: Retrospective review of paediatric CF pts who underwent azithromycin
treatment for at least one year until the end of year 2008.
Results: Sixteen pts (8 female; mean age at azithromycin initiation 13 years
1 month) received azithromycin for a mean duration of 16.5 months. In the year
preceding its initiation, 11 pts were chronically colonized with P. aeruginosa.
FEV 1% predicted comparison at azithromycin start and one year after revealed
improvement in 6 pts and decrease in 5 pts. BMI percentile had an increase in
2 pts and 9 pts suffered no change. A decrease in the number of hospitalization
and intravenous antibiotic days was seen in 7 pts and no change was observed in
7 pts during the ﬁrst treatment year. Eleven pts had a decrease in the number of
oral antibiotic treatment days. No signiﬁcant change was seen in the percentage of
mucoid P. aeruginosa isolates during the study period. No major adverse effects
were observed.
Conclusions: In our study the major clinical beneﬁts of azithromycin treatment were
observed in the occurrence of pulmonary exacerbations requiring hospitalization
and intravenous antibiotics as well as additional oral antibiotic courses.
